{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "NOK", "marketState": "POSTPOST", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 9.63, "exchange": "CXE", "longName": "Targovax ASA", "exchangeTimezoneName": "Europe/London", "market": "gb_market", "regularMarketTime": 1683183870, "regularMarketPreviousClose": 9.63, "fullExchangeName": "Cboe UK", "financialCurrency": "NOK", "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 4.2734103, "fiftyTwoWeekLowChangePercent": 0.79778564, "fiftyTwoWeekRange": "5.35659 - 5.35659", "fiftyTwoWeekHighChange": 4.2734103, "fiftyTwoWeekHighChangePercent": 0.79778564, "fiftyTwoWeekLow": 5.35659, "fiftyTwoWeekHigh": 5.35659, "earningsTimestamp": 1683781200, "earningsTimestampStart": 1683781200, "earningsTimestampEnd": 1683781200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.78, "bookValue": 0.014, "fiftyDayAverage": 5.35659, "fiftyDayAverageChange": 4.2734103, "fiftyDayAverageChangePercent": 0.79778564, "twoHundredDayAverage": 5.35659, "twoHundredDayAverageChange": 4.2734103, "twoHundredDayAverageChangePercent": 0.79778564, "priceToBook": 687.8571, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1495090800000, "priceHint": 2, "regularMarketChange": 0.0, "symbol": "TRVXO.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Vollsveien 19", "city": "Lysaker", "zip": "1366", "country": "Norway", "phone": "47 21 39 88 10", "website": "https://www.targovax.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Targovax ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system. The company has collaboration agreements with university of Kansas Cancer Center. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Dr. Erik Digman Wiklund", "title": "Chief Exec. Officer", "fiscalYear": 2022, "totalPay": {"raw": 3791000, "fmt": "3.79M", "longFmt": "3,791,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lubor  Gaal Ph.D.", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 3223272, "fmt": "3.22M", "longFmt": "3,223,272"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Victor  Levitsky M.D., Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2022, "totalPay": {"raw": 849000, "fmt": "849k", "longFmt": "849,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ingunn Munch Lindvig", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2022, "totalPay": {"raw": 1966000, "fmt": "1.97M", "longFmt": "1,966,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lone  Ottesen M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2022, "totalPay": {"raw": 4149000, "fmt": "4.15M", "longFmt": "4,149,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ola  Melin", "title": "VP & Head of Manufacturing", "fiscalYear": 2022, "totalPay": {"raw": 2166000, "fmt": "2.17M", "longFmt": "2,166,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jon Amund Eriksen M.Sc., MSc", "title": "Special Advisor", "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Gustav  Gaudernack Ph.D.", "title": "Chief Scientific Adviser", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Thomas Birkballe Hansen", "title": "VP & Head of Research", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peter  Skorpil Ph.D.", "title": "VP of Bus. Devel.", "fiscalYear": 2017, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}